The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 677-686

  He, Y L ^a   Sabo, R ^b   Campestrini, J ^c   Wang, Y ^b   Ligueros Saylan, M ^b   Lasseter, K C ^d   Dilzer, S C ^d   Howard, D ^b   Dole, W P ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

^d PharmaNet Development Group Inc   (United States)

Author keywords

Chronic liver disease; Dipeptidyl peptidase IV inhibitor; Pharmacokinetics; Type 2 diabetes; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; LAY 151; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE;

ADAMANTANE; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD26; AREA UNDER CURVE; CHRONIC DISEASE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER DISEASES; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 34250307638     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0312-6     Document Type: Article

References (24)

1. Ahren B (1998) Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20:642-651
2. Ahren B, Gomis R, Standl E, Mills D,Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
3. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D,Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
4. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, Alberino F, Gatta A (1994) Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154:201-205
5. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
6. Deacon CF, Holst JJ (2006) Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 38:831-844
7. Food and Drug Administration (2003) Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. U.S. Department on Health and Human Services. http://www.fda.gov/ cber/guidelines.htm. Accessed on March 26, 2007
8. Hatorp V, Walther KH, Christensen MS, Haug-Pihale G (2000) Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 40:142-152
9. He Y, Balch A, Campestrini J, Rivere GJ, Seera D, Prasad P (2005) Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes. Clin Pharmacol Ther 77:56
10. Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430-441
11. Krarup T, Holst JJ, Larsen KL (1985) Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 249:E195-200
12. Lebovitz HE (2002) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18[Suppl 2]:S23-29
13. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
14. McLean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42-69
15. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y (1999) Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847
16. Morgan DJ, McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 29:370-391
17. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
19. Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37:399-431
20. Sansoe G, Ferrari A, Castellana CN, Bonardi L, Villa E, Manenti F (2002) Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis. Clin Sci 102:91-98
21. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258
22. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
23. Wagstaff AJ,Goa KL (2002) Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837
24. Williams RL, Mamelok RD (1980) Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 5:528-547